- Open Access
Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc
© Scorsetti et al; licensee BioMed Central Ltd. 2010
- Received: 5 July 2010
- Accepted: 15 October 2010
- Published: 15 October 2010
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
To report acute toxicity, initial outcome results and planning therapeutic parameters in radiation treatment of advanced lung cancer (stage III) with volumetric modulated arcs using RapidArc (RA).
Twenty-four consecutive patients were treated with RA. All showed locally advanced non-small cell lung cancer with stage IIIA-IIIB and with large volumes (GTV:299 ± 175 cm3, PTV:818 ± 206 cm3). Dose prescription was 66Gy in 33 fractions to mean PTV. Delivery was performed with two partial arcs with a 6 MV photon beam.
From a dosimetric point of view, RA allowed us to respect most planning objectives on target volumes and organs at risk. In particular: for GTV D1% = 105.6 ± 1.7%, D99% = 96.7 ± 1.8%, D5%-D95% = 6.3 ± 1.4%; contra-lateral lung mean dose resulted in 13.7 ± 3.9Gy, for spinal cord D1% = 39.5 ± 4.0Gy, for heart V45Gy = 9.0 ± 7.0Gy, for esophagus D1% = 67.4 ± 2.2Gy. Delivery time was 133 ± 7s. At three months partial remission > 50% was observed in 56% of patients. Acute toxicities at 3 months showed 91% with grade 1 and 9% with grade 2 esophageal toxicity; 18% presented grade 1 and 9% with grade 2 pneumonia; no grade 3 acute toxicity was observed. The short follow-up does not allow assessment of local control and progression free survival.
RA proved to be a safe and advantageous treatment modality for NSCLC with large volumes. Long term observation of patients is needed to assess outcome and late toxicity.
- Advanced NSCLC
- Gross Tumor Volume
- Advanced Lung Cancer
- Contralateral Lung
- Analytical Anisotropic Algorithm
Lung cancer remains the major cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) account for at least 80% of all lung tumors and about 30% of them present with unresectable locally advanced disease at diagnosis (stage IIIA-IIIB) . Until the mid 1980s standard treatment of patients with inoperable locally advanced NSCLC consisted of radiotherapy (RT) alone with a median survival time of 10 months. From data about lung cancer population diagnosed in the second half of 1990s, overall survival at one and two years was estimated of 36% and 12% respectively.
Rates at 2 and 5 years of 15% and 5% respectively . In attempts to improve the survival in these patients, chemotherapy was added to external beam irradiation. Several trials have been positive in favour of combined therapy [4–6]. More recently, other clinical trials have shown that, in selected patients (good performance status, age ≤ 75 years and minimal weight loss) concomitant platinum-based chemo-radiotherapy is feasible with improvement in progression-free survival and overall survival (OS) in comparison with sequential chemo-radiotherapy (OS 4 years 21% vs. 14%) . However, survival for patients with unresectable locally advanced NSCLC is extremely poor with high rates of loco-regional failure. Recent trials suggest that dose escalation RT could improve loco-regional control with likely benefit on overall survival [8–10]. Rengan et al reviewed the treatment of stage III tumors with large gross tumor volumes (GTV) using 3D-CRT, founding 10 Gy increase in dose to be correlated with a 36.4% decrease in local failure rates . Unfortunately, the large volume of tumor makes dose escalation difficult when using 3D-CRT, since, to avoid treatment related complications such as severe pneumonitis, it is necessary to keep the mean lung dose (MLD) below 20Gy approximately .
More recently, the development of intensity modulated radiotherapy (IMRT) makes it possible to deliver a high therapeutic effective dose to the target volume with maximum preservation of surrounding normal tissues. Many studies have compared IMRT and 3D-CRT plans for patients with large unresectable locally advanced NSCLC. Results show statistically significant differences in V20, V30 and MLD for contralateral lung with the values in the IMRT plans being lower. The benefits seemed most pronounced in medium to large tumours .
A recent retrospective clinical trial of MSKCC reported a 2-year local control and overall survival of 58% and 58% respectively and a median survival time of 25 months for patients with inoperable stage III lung cancer and treated with 70 Gy (range 60-90 Gy) using IMRT . The results of this study suggest that dose escalation could have an effect not only on local control but also on survival.
To implement dose escalation strategy on NSCLC, advanced IMRT delivery technologies such as Helical Tomotherapy were used and compared with three-dimensional conformal radiotherapy in the clinical practice[14, 15]. Both Helical Tomotherapy, and to a lesser extent conventional three-dimensional conformal radiotherapy, have shown the potential to significantly decrease radiation dose to lung and other normal structures in the treatment of NSCLC, providing important implications, in terms of acceptable acute toxicities recorded, for dose escalation strategies in the future[15, 16]. In a report of volumetric changes, measured in the primary tumor on megavoltage-computed tomography (MVCT) during chemoradiation, Helical Tomotherapy showed also to be effective in reduce tumour volume in NSCLC.
RapidArc(RA), a volumetric modulated arc therapy based on the original investigation of K. Otto , has been recently introduced in clinical practice in several institutes after an intensive validation at planning level, compared to IMRT or other approaches, in a series of studies including brain tumours, prostate, head and neck, mesothelioma, cervix uteri and other indications [19–25].
RA is implemented as the Progressive Resolution Optimisation (PRO) algorithm in the Eclipse planning system by Varian Medical System (Palo Alto, California, USA). The optimisation process is based on an iterative inverse planning process that aims to simultaneously optimise the instantaneous multi-leaf collimator (MLC) positions, the dose rate, and the gantry rotation speed in order to achieve the desired dose distribution.
In this study, our aim was to investigate the potential of RA to deliver a therapeutic dose to large volume unresectable NSCLC. We also investigated the possibility of sparing lung tissue, esophagus, heart and spinal cord using RA with the aim of paving the way for further study of dose escalation In the present study, acute toxicities and initial outcome results, were evaluated and reported.
Patients and procedures
Summary of patients characteristics at treatment start. Values are expressed in number of patients when not otherwise specified
Number of patients
(median and range)
67 y (43-84)
Radiation Dose Prescription
The patient's general conditions (age, performance status, weight loss and co-morbidity) were recorded. Total body computed tomography (CT) scan, FDG positron emission tomography (PET) and bone scans were performed in each patient before treatment. In the present population of study, FDG PET was not performed in treatment position and PET images were used by clinician only to obtain a complete stadiation of the patients before treatment. Pathological diagnosis was made by CT-guided fine needle biopsy in 8 patients; 6 patients underwent mediastinoscopy; 4 patients underwent thoracotomy and 6 patients underwent bronchoscopy. Sequential or concomitant chemotherapy was performed in patients of one or more of the following: i) age ≤ 75 years, ii) PS 0-1, iii) minimum weight loss (< 10% 6 months before diagnoses) and iv) Absence of important co-morbidity. Radiotherapy alone was prescribed in patients of one or more of the following:.i) age ≥ 75 years, ii) PS 1-2, iii) minimum weight loss (> 10% 6 months before diagnoses.
All patients received a planning CT scan and were immobilized in a supine position within a personal body-fix pillow. During the scan, and the treatment, patients breathed freely, with the indication to maintain a breathing cycle as regular as possible. The Gross Tumor Volume (GTV) consisted of all known sites of disease with no elective nodal targets. The GTV was defined "large" if it was ≥ 100 cc. The PTV was defined applying an isotropic margin of 8 mm from the primary tumor and of 5 mm from the involved regional lymph nodes. The protocol of treatment started with patients presenting stage III lung cancer in the upper quadrant, and with target volume: > 400 cm3. According to Liu et al.  the motion of these lesions is lower than 3 mm, therefore the use of 4D techniques is unnecessary. Furthermore daily kV-cone beam CT (CBCT) is performed before RT treatment in order to verify the correct patient position and the target motion (considering the CBCT as a slow CT that includes the lesion motion). Despite daily image guided have already shown in lung the advantage to quantify the volumetric tumour response during treatment , in the present study CBCTs were utilized only for patient daily set-up correction.
Summary of DVH analysis for CTV and PTV
299 ± 175
818 ± 206
101.0 ± 1.2
100.0 ± 0.0
105.6 ± 1.7
105.6 ± 1.6
6.3 ± 1.4
9.1 ± 1.3
96.7 ± 1.8
91.6 ± 2.2
99.6 ± 0.6
94.6 ± 4.1
0.7 ± 1.3
0.7 ± 1.7
Summary of DVH analysis for organs at risk
Volume [cm 3 ]
1717 ± 549
30.4 ± 7.0
V 20Gy [%]
52.8 ± 8.9
Volume [cm 3 ]
1945 ± 517
< 15 Gy
13.7 ± 3.9
V 20Gy [%]
21.1 ± 6.1
Volume [cm 3 ]
39 ± 16
D 1% [Gy]
< 45 Gy
39.5 ± 4.0
Volume [cm 3 ]
715 ± 161
V 45Gy [%]
9.0 ± 7.0
V 50Gy [%]
6.9 ± 6.3
Volume [cm 3 ]
37 ± 13
V 55Gy [%]
33.3 ± 10.0
D 1% [Gy]
< 70 Gy
67.4 ± 2.2
Volume [cm 3 ]
29588 ± 7788
9.5 ± 2.7
V 10Gy [%]
27.6 ± 7.7
All patients were treated with conventional fractionation (2 Gy/day) with no planned treatment breaks. Total dose prescription was 66Gy/33 fractions (with the exception of two patients, one receiving 50Gy and one 60Gy due to OARs limiting factors). In all cases dose normalization was set to mean dose to PTV.
Plans were optimized for two partial isocentric arcs for a Clinac 2100 equipped with a Millennium-120 MLC (120 leaves with a resolution at isocentre of 5 mm for the inner 20 cm and 10 mm for the outer 2 × 10 cm) and a beam energy of 6MV. The arc lengths were set in order to avoid entrance from the contra-lateral lung (depending on target location and extension), and to avoid the posterior entrances, where the couch bars were positioned. For further details on the RapidArc technique see references [15, 16].
Plan optimization was performed requiring PTV coverage of 95%-107%. With regard to OARs, the primary objectives were: Spinal cord: D1% < 46Gy; Contra lateral lung: V20Gy < 30%, mean dose < 15Gy; Oesophagus: D1% < 70 Gy. Secondary objectives: Ipsilateral lung: V20Gy as low as possible
Oesophagus: V55Gy < 30%; Heart: V50Gy < 20%, V45Gy < 30%.
If the primary objectives were not fulfilled, the prescribed dose was reduced. One patient received 60Gy and another only 50Gy due to organs at risk dose limiting factors.
All dose distributions were computed with the Analytical Anisotropic Algorithm (AAA, version 8.6) implemented in the Eclipse planning system with a calculation grid resolution of 2.5 mm.
All patients were evaluated weekly with physical and hematologic examination during radiation treatment. Acute and late toxicity events were scored according to the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC) criteria . Acute reactions included those occurred during or within the first 4 months after the start of radiation treatment and late complications those occurred or persisted after 4 months.
Evaluation of tumor response was performed 45 days after the end of treatment and then every 3 months thereafter with total body CT and/or PET/CT scans. Tumor response was defined according to the Response Evaluation Criteria in Solid Tumor (RECIST) . Clinical and radiographic evidence of local or distant tumor recurrence was recorded.
Technical features of treatments have been reported in terms of main delivery parameters (number of arcs, control point size, MU, MU/deg and MU/Gy, Dose Rate, Gantry speed, Collimator angle, beam-on and treatment time); beam-on and treatment times are defined without inclusion of patient positioning and imaging procedures and were scored from the record and verify electronic system. Results of pre-treatment plan quality assurance are reported as Gamma Agreement Index (GAI), i.e. the percentage of modulated field area passing the γ-index criteria of Low  with thresholds on dose difference set to Δ = 3% of the significant maximum dose, and on Distance to Agreement set to DTA = 3 mm. Measurements and analysis were performed by means of the GLAaS methodology described in [30, 31] based on absorbed dose to water from EPID measurements.
Dosimetric quality of the treatments was measured from dose volume histogram (DVH) analysis. For PTV the following data was reported: target coverage (D1%, D99%, V95%, V107%), homogeneity (D5%-D95%). For OARs, the mean dose, the maximum dose (D1%) and appropriate values of VxGy (volume receiving at least × Gy) were scored.
Twenty-four patients with large volume NSCLC were treated with a median dose of 66 Gy (range:50-66 Gy) or more using RA from May 2009 to September 2009. All patients had tumors that were unresectable for site and stage. Eleven patients were stage IIIB and 13 patients stage IIIA. Eleven selected patients (age < 70 years, minimum weight loss < 10% 6 months before diagnosis, and PS 0) were treated with concurrent platinum-based chemo-radiation therapy. Eight patients were treated with sequential chemo-radiotherapy, and 5 patients with RT alone because unfit for chemotherapy or elderly.
Only early results are available regarding clinical outcomes. As planned, there were no interruptions during the course of the radiation treatment. No patients had acute skin toxicity. Esophageal toxicity was mild. No Grade 3 toxicity occurred. Grade 1 and Grade 2 acute esophageal toxicity occurred in 22/24 and 2/24 patients respectively. Persistent cough requiring narcotic and antitussive agents occurred in 10/24 patients. For sub-acute toxicity, asymptomatic pneumonia occurred in 6 patients (four grade 1, and two grade 2) who underwent concurrent chemo-radiotherapy at 45 days from the end of treatment and regressed with antibiotic therapy, without hospitalization. Compared with exclusive radiotherapy group, hematologic toxicity was higher in Chemoradiation one, but there was not acute toxicity > Grade 3 or interruptions. There wasn't an important effect of side effects on weight loss for the population of study and PS was not significantly reduced during treatment. The median follow-up time was 6 months.
Technical characteristics of RapidArc and conventional plans
Number of arcs or fields
Arcs length [°] whole plan
401 ± 166
Delivery time [s]
133 ± 7
391 ± 68
190 ± 38
Dose Rate [MU/min]
239 ± 51
Gantry speed [deg/sec]
4.79 ± 0.02
Collimator angle [°]
19 ± 8
Mean leaf aperture [cm]
5.3 ± 1.5
Mean CP area [cm 2 ]
98 ± 30
Mean field area [cm 2 ]
337 ± 91
Dosimetric data showed that RapidArc obtained the achievement with respect to planning objectives for most of the parameters considered. In particular, the target coverage and dose homogeneity are well achieved, even in regions with highly demanding heterogeneities (GTV well within the thresholds of 95% and 107%). In terms of organs at risk the contralateral lung presented promising results, while keeping the maximum significant dose to the spinal cord well below the tolerance level. Heart irradiation was not of major concern for the selected patients due to the relatively cranial target location. The oesophagus volume irradiated to doses higher than 55Gy is in average higher than objective by about 3%, but this value is largely dependent on the organ volume included inside the target volume. As expected from an intensity modulation arc technique the low dose bath is not negligible, showing about 8000 cm3 of tissue irradiated at 10Gy dose level.
Pre-treatment quality assurances of RA plans resulted in an average gamma agreement index GAI 3% superior to the acceptance threshold of 95% set as a reference in our institute.
Despite an improvement in survival the prognosis of patients with unresectable local advanced NSCLC (stage IIIA-IIIB) remains poor both for locoregional failure and for distant metastatic disease. Concurrent chemo-radiation is at present the standard of care. Given that local recurrence is the leading cause of death in this patient population, techniques for improving local control may have a positive impact on survival rates and quality of life. The value of dose escalation was demonstrated in a study from MSKCC; Rengan et al founded that a 10 Gy increased in dose correlated to a 36.4% decrease in local failure rates . Unfortunately, the extension of disease and the presence of surrounding HT makes it often difficult to deliver high doses with curative intent.
Based on the results of an intensive program of pre-clinical investigations performed at planning level [19–25] for assessing the reliability and potential benefit of RA, this technique has been used in clinical practice for a variety of indications at our Institute since November 2008. The present study reports the early findings from the treatment of a group of 24 patients affected by advanced lung cancer irradiated with RapidArc.
The main objective in the initial clinical introduction of RA is the evaluation of the possibility to provide RT treatments respecting a set of planning objectives. These results should be achieved without introducing elements of potential confusion like alterations of the fractionation schemes (acceleration or hypo-fractionation for example) or dose escalation . Further studies will assess the elements of improvement once the safety of the new approach is consolidated in routine practice. These results could enable the activation of a second phase dose trial aiming to push RapidArc towards improved sparing of organs at risk, particularly the contra-lateral lung.
Having achieved the result of respecting or improving most of the planning objectives, RapidArc confirmed also some advantages at a logistical level. It provided a significant efficiency in dose delivery treatment time,. This is a particularly important point for patients presenting advanced lung cancer, who might have breathing difficulties in supine position, or even coughing if lying for a long time: shortening the time spent on the couch permits the treatment for this class of patients.
From the clinical point of view, the data presented here are encouraging, confirming that RA can be considered as a safe modality for this category of patients having proved limited impact in terms of acute toxicity [32, 33]. The smoother process of RA and its potential reduction in acute toxicity could also lead to a more uniform duration of treatments, reducing the risk of unscheduled and undue interruptions.
In particular, the authors point out the extension of disease to be greater than other population finding in literature. Sura et al.  report mean PTV volume of 459 cm3, much smaller than our series, where mean PTV volume was 818 cm3, thus corroborating our results.
It is obvious that the present study cannot be considered as conclusive and that long-term observation of patients is needed to define outcome and late toxicity. These preliminary results are encouraging additional experience in this field. Further investigations will aim to look at the long term clinical outcome and late toxicity as well as improvements in sparing of the organs at risk.
Twenty-four patients with large volume unresectable locally advanced lung cancer were treated with RA at Istituto Clinico Humanitas. Quality of treatments resulted in a general fulfilment of the planning objectives. Clinical outcome for early acute toxicity showed limited events. Future investigations will aim to increase sparing of organs at risk and to look to long-term outcome based on the fact that the first phase has achieved the primary goal of demonstrating the safety and efficacy of RA.
- Jamal A, Twari RC, Murray T, et al.: Cancer statistic. CAJ Clinic 2004,54(8):29.Google Scholar
- Graham MV, Pajak T, Herskovic A, et al.: Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer. IJROPB 1995, 31: 819-825.Google Scholar
- Sant M, Allemani C, Santaquilani M, et al.: EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009, 45: 931-91. 10.1016/j.ejca.2008.11.018View ArticlePubMedGoogle Scholar
- Dilmann RO, Seagren SL, Propert KJ, et al.: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. NEJM 1990, 323: 940-945. 10.1056/NEJM199010043231403View ArticleGoogle Scholar
- Le Chavalier T, Arriagada R, Quoix E, et al.: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: firs analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991, 83: 417-423. 10.1093/jnci/83.6.417View ArticleGoogle Scholar
- Sause W, Kolesar P, Taylor IVS, et al.: Final results of Phase III trial in regionally advanced unresectable non small cell lung cancer. Chest 2000, 117: 358-364. 10.1378/chest.117.2.358View ArticlePubMedGoogle Scholar
- Curran WJ, Scott CB, Langer CJ, et al.: Long term benefit is observed in a phase III comparaison of sequential vs concurrent chemoradiation for patients with unresectable stage III NSCLC: RTOG 94-10. Proc Am Soc Clin Oncol 2003, 22: 621a. abstr 2499Google Scholar
- Rosenzeweig KE, Fox JL, Yorke E, et al.: Results of Phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non small cell lung carcinoma. Cancer 2005, 103: 2118-2127. 10.1002/cncr.21007View ArticleGoogle Scholar
- Rengan R, Rosenzweig KE, Venkatraman E, et al.: Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 60: 741-7.View ArticlePubMedGoogle Scholar
- Hayman JA, Martel MK, Ten Haken RK, Normolle DP, Todd RF, Littles JF, Sullivan MA, Possert PW, Turrisi AT, Lichter AS: Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001,19(1):127-36.PubMedGoogle Scholar
- Kwa SL, Lebesque JV, Theuws JC, et al.: Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 1998, 42: 1-9.View ArticlePubMedGoogle Scholar
- Liu HH, Wang X, Dong L, et al.: Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004,58(4):1268-79.View ArticlePubMedGoogle Scholar
- Sura S, Gupta V, Yorke E, Jackson A, Amols H, Rosenzweig KE: Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 2008, 87: 17-23. 10.1016/j.radonc.2008.02.005PubMed CentralView ArticlePubMedGoogle Scholar
- Mehta M, Scrimger R, Mackie R, et al.: A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001, 49: 23-33.View ArticlePubMedGoogle Scholar
- Scrimger RA, Tomé WA, Olivera GH, et al.: Reduction in radiation dose to lung and other normal tissues using helical tomotherapy to treat lung cancer, in comparison to conventional field arrangements. Am J Clin Oncol 2003, 26: 70-8. 10.1097/00000421-200302000-00014View ArticlePubMedGoogle Scholar
- Bral S, Duchateau M, Versmessen H, et al.: Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy. Cancer 2010, 116: 241-50.PubMedGoogle Scholar
- Bral S, Duchateau M, De Ridder M, et al.: Volumetric response analysis during chemoradiation as predictive tool for optimizing treatment strategy in locally advanced unresectable NSCLC. Radiother Oncol 2009, 91: 438-42. 10.1016/j.radonc.2009.03.015View ArticlePubMedGoogle Scholar
- Otto K: Volumetric Modulated Arc Therapy: IMRT in a single arc. Med Phys 2008, 35: 310-317. 10.1118/1.2818738View ArticlePubMedGoogle Scholar
- Scorsetti M, Bignardi M, Clivio A, Cozzi L, Fogliata A, Lattuada P, Mancosu P, Navarria P, Nicolini G, Urso G, Vanetti E, Vogorito S, Santoro A: Volumetric modulation arc radiotherapy compared with static gantry IMRT for malignant pleural mesothelioma tumour: a feasibility study. Int J Radiat Oncol Biol Phys 2010,77(3):942-9.View ArticlePubMedGoogle Scholar
- Cozzi L, Dinshaw KA, Shrivastava SK, Mahantshetty U, Engineer R, Deshpande DD, Jamema SV, Vanetti E, Clivio A, Nicolini G, Fogliata A: A treatment planning study comparing volumetric arc modulation with RapidArc and fixed field IMRT for cervix uteri radiotherapy. Radiother Oncol 2008, 89: 180-91. 10.1016/j.radonc.2008.06.013View ArticlePubMedGoogle Scholar
- Fogliata A, Clivio A, Nicolini G, Vanetti E, Cozzi L: Intensity modulation with photons for benign intracranial tumours: a planning comparison of volumetric single arc, helical arc and fixed gantry techniques. Radiother Oncol 2008, 89: 254-62. 10.1016/j.radonc.2008.07.021View ArticlePubMedGoogle Scholar
- Kjær-Kristoffersen F, Ohlhues L, Medin J, Korreman S: RapidArc volumetric modulated therapy planning for prostate cancer patients. Acta Oncol 2008: 1-6.Google Scholar
- Mancosu P, Navarria P, Bignardi M, Cozzi L, Fogliata A, Lattuada P, Santoro A, Urso G, Vigorito S, Scorsetti M: Re-irradiation of metastatic spinal cord compression: A feasibility study by volumetric-modulated arc radiotherapy for in-field recurrence creating a dosimetric hole on the central canal. Radiother Oncol 2010,77(3):942-9.Google Scholar
- Bignardi M, Cozzi L, Fogliata A, Lattuada P, Mancosu P, Navarria P, Urso G, Vigorito S, Scorsetti M: Critical appraisal of volumetric modulated arc therapy in stereotactic body radiation therapy for metastases to abdominal lymph nodes. Int J Radiat Oncol Biol Phys 2009,75(5):1570-7.View ArticlePubMedGoogle Scholar
- Verbakel W, Cuijpers J, Hoffmans D, Bieker M, Slotman B: Volumetric intensity modulated arc therapy versus conventional IMRT in head and neck cancer: A comparative planning and dosimetric study. Int J Radiat Oncol Biol Phys 2009, 74: 252-9.View ArticlePubMedGoogle Scholar
- Liu HH, Balter P, Tutt T, et al.: Assessing respiration-induced tumor motion and internal target volume using 4DCT for RT of lung cancer. Int J Radiat Oncol Biol Phys 2007, 68: 531-540.View ArticlePubMedGoogle Scholar
- Cox J, Stetz J, Pajak TF: Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 1995, 31: 1341-1346.View ArticlePubMedGoogle Scholar
- Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumor. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United State, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92: 205-216. 10.1093/jnci/92.3.205View ArticlePubMedGoogle Scholar
- Low DA, Harms WB, Mutic S, Purdy JA: A technique for quantitative evaluation of dose distributions. Med Phys 1998, 25: 656-661. 10.1118/1.598248View ArticlePubMedGoogle Scholar
- Nicolini G, Vanetti E, Clivio A, Fogliata A, Korreman S, Bocanek J, Cozzi L: The GLAaS algoritm for portal dosimetry and quality assurance of RapidArc, an intensity modulated rotational therapy. Radiat Oncol 2008, 3: 24. 10.1186/1748-717X-3-24PubMed CentralView ArticlePubMedGoogle Scholar
- Nicolini G, Fogliata A, Vanetti E, Clivio A, Cozzi L: GLAaS: an absolute dose calibration algorithm for an amorphous silicon portal imager. Applications to IMRT verifications. Med Phys 2006, 33: 2839-2851. 10.1118/1.2218314View ArticlePubMedGoogle Scholar
- Richetti A, Fogliata A, Clivio A, Nicolini G, Pesce G, Salati E, Vanetti E, Cozzi L: Neoadjuvant chemo-radiation of rectal cancer with volumetric modulated arc therapy: summary of technical and dosimetric features and early clinical experience. Radiat Oncol 2010, 5: 14. 10.1186/1748-717X-5-14PubMed CentralView ArticlePubMedGoogle Scholar
- Pesce GA, Clivio A, Cozzi L, Nicolini G, Richetti A, Salati E, Valli M, Vanetti E, Fogliata A: Early clinical experience of radiotherapy of prostate cancer with volumetric modulated arc therapy. Radiation Oncology 2010, 5: 54. 10.1186/1748-717X-5-54PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.